Partner Headlines - ARNA

  1. Wednesday's Mid-Day Movers: Does The U.S. Benefit From Iran Deal?; ...

    Benzinga
  2. Wednesday's Mid-Day Movers: Does The U.S. Benefit From Iran Deal?; ...

    Benzinga
  3. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  4. Mid-Morning Market Update: Markets Mostly Higher; Bank Of America ...

    Benzinga
  5. Sportsman's Warehouse, Bob Evans, Peabody Energy Lead Tuesday's ...

    Benzinga
  6. 5 New Biotech Developments Worth Watching

    Benzinga
  7. Morning Market Gainers

    Benzinga
  8. Benzinga's Top #PreMarket Gainers

    Benzinga
  9. Pharmacological Advancements in Neuroscience Drug Discovery & ...

    Benzinga
  10. Orexigen Soars On Obesity Drug's Surprise Health Boon

    IBD
  11. Morning Market Losers

    Benzinga
  12. Benzinga's Top #PreMarket Losers

    Benzinga
  13. 10 Stocks You Should Be Watching Today

    Benzinga
  14. Arena Pharmaceuticals Misses Q4 Expectations

    Benzinga
  15. Earnings Scheduled For March 2, 2015

    Benzinga
  16. CNBC's Stock Pops & Drops From January 21

    Benzinga
  17. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  18. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  19. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  20. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  21. Morning Market Losers

    Benzinga
  22. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  23. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  24. Benzinga's Top #PreMarket Losers

    Benzinga
  25. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  26. 5 Obesity Stocks Investors Are Watching

    Benzinga
  27. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  28. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  29. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  30. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  31. Morning Market Gainers

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  34. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  35. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  36. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  37. Benzinga's Top #PreMarket Gainers

    Benzinga
  38. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  39. Earnings Scheduled For November 3, 2014

    Benzinga
  40. 3 Pharma Companies Fighting Obesity

    Benzinga
  41. Benzinga's Top #PreMarket Gainers

    Benzinga
  42. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  43. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  44. Earnings Scheduled For August 1, 2014

    Benzinga
  45. Benzinga's Top #PreMarket Losers

    Benzinga
  46. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  47. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  48. Benzinga's Top #PreMarket Losers

    Benzinga
  49. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  50. FDA delays Orexigen drug

    IBD
  51. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  52. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  53. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  54. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  55. Earnings Scheduled For May 12, 2014

    Benzinga
  56. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  57. Benzinga's Top #PreMarket Losers

    Benzinga
  58. Earnings Scheduled For February 27, 2014

    Benzinga
  59. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  60. Top Trending Tickers On StockTwits For February 14

    Benzinga
  61. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  62. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  63. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  64. The Top Five Drug Launches Of 2013

    IBD
  65. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  66. Benzinga's Top #PreMarket Gainers

    Benzinga
  67. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  68. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  69. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  70. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  71. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  72. Benzinga's Top #PreMarket Losers

    Benzinga
  73. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  74. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  75. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  76. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  77. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  78. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  79. Benzinga's Top Pre-Market Losers

    Benzinga
  80. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  81. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  82. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  83. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  84. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  85. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  86. Stocks Hitting 52-Week Lows

    Benzinga
  87. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  88. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  89. Stocks Hitting 52-Week Lows

    Benzinga
  90. Stocks Hitting 52-Week Lows

    Benzinga
  91. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  92. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  93. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  94. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  95. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  96. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  97. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  98. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  99. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  100. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!